Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,512.38 -3.89 -0.03%
TOPIX 1,171.40 -1.97 -0.17%
HANG SENG 22,760.24 64.23 0.28%

Sofia Vergara Encourages Individuals with Hypothyroidism to "Follow the Script"



   Sofia Vergara Encourages Individuals with Hypothyroidism to "Follow the
                                   Script"

National Empowerment Campaign with AbbVie Focuses on Hypothyroidism and the
Importance of Patient-Physician Dialogue

PR Newswire

NORTH CHICAGO, Ill., April 17, 2013

NORTH CHICAGO, Ill., April 17, 2013 /PRNewswire/ -- (NYSE: ABBV) -
Emmy-nominated actress Sofia Vergara is helping to raise awareness about the
importance of diagnosing and treating hypothyroidism, a thyroid condition that
affects millions of Americans, through a new campaign called "Follow the
Script." The campaign, made possible by AbbVie, aims to educate individuals
with hypothyroidism about the importance of being consistent with the
treatment their doctor prescribes, and provides a "script" to ensure they
consistently receive the medication prescribed by their doctor when they visit
the pharmacy.

"In 2000, I was diagnosed with thyroid cancer and had to have my thyroid
removed. As a result, I have a hypothyroid condition and need to take medicine
to treat it," said Vergara. "In my career, I'm known to ad lib and go
off-script-but not when it comes to my health. I make sure to 'Follow the
Script' so I get exactly what my doctor prescribed. This is so important to
me, because you can't enjoy what you have without your health."

To help increase awareness about hypothyroidism, connect with the
hypothyroidism community, and encourage others to take an active role in their
health, Sofia shares her story at www.followthescriptcampaign.com. The "Follow
the Script" website also features interactive polls, symptom and treatment
information, helpful 'scripts' for speaking with your doctor and pharmacist,
as well as stories and videos from other individuals with hypothyroidism.
Visitors can also share their own experiences and learn how to become involved
as a Synthroid® (levothyroxine sodium tablets, USP) patient volunteer.

"AbbVie is proud to work with Sofia Vergara and support this education
campaign," said Maria Rivas, M.D., Vice President of Global Medical Affairs at
AbbVie, the makers of Synthroid. "Hypothyroidism is a complex condition that
can be managed with the right tools and information. The hope and aim of this
campaign is to increase awareness about hypothyroidism and empower patients to
engage in dialogue and work with their healthcare providers throughout their
treatment."

Thyroid conditions affect an estimated 30 million individuals in the U.S.[i],
and are especially prevalent among women. Approximately one in every eight
women will develop a thyroid condition in her lifetime[ii]. Hypothyroidism, a
condition in which the thyroid gland does not produce enough thyroid hormone,
can be managed with levothyroxine[iii].

"Your thyroid can affect the way you feel, look and sound," said Jordan L.
Geller, M.D., Vergara's endocrinologist. "I work with my patients to ensure
they understand their hypothyroidism diagnosis and the medication and dose
that are right for them."

The United States Food and Drug Administration has determined that some, but
not all, levothyroxine products are interchangeable. A levothyroxine product
that is not therapeutically equivalent may not have the same effect on a
patient's thyroid hormone levels. However, levothyroxine products that are
classified as therapeutically equivalent can be substituted with a physician's
approval[iv].

About Synthroid
SYNTHROID® (levothyroxine sodium tablets, USP) is a prescription synthetic
thyroid hormone that is used to treat a condition called hypothyroidism. It is
intended to replace a hormone that is normally produced by your thyroid gland.
Generally, thyroid replacement therapy is to be taken for life.

Important Safety Information

  o Thyroid hormones, including SYNTHROID, should not be used either alone or
    in combination with other medicines for the treatment of obesity or weight
    loss. In patients with normal thyroid levels, doses of SYNTHROID within
    the typical range used for hormone replacement are not effective for
    weight loss. Larger doses may result in serious or even life-threatening
    effects, especially when used in combination with certain other drugs used
    to reduce appetite.
  o Notify your physician if you are allergic to any foods or medicines, are
    pregnant or intend to become pregnant, are breast-feeding or are taking
    any other medications, including prescription and over-the counter
    preparations.
  o Notify your physician of any other medical conditions you may have,
    particularly heart disease, diabetes, clotting disorders, and adrenal or
    pituitary gland problems. Your dose of medications used to control these
    other conditions may need to be adjusted while you are taking SYNTHROID.
    If you have diabetes, monitor your blood and/or urinary glucose levels as
    directed by your physician and immediately report any changes to your
    physician. If you are taking anticoagulants (blood thinners), your
    clotting status should be checked frequently.
  o Use SYNTHROID only as prescribed by your physician. Do not discontinue or
    change the amount you take, or how often you take it, unless directed to
    do so by your physician.
  o Agents such as iron and calcium supplements and antacids can decrease the
    absorption of levothyroxine sodium tablets. Therefore, levothyroxine
    sodium tablets should not be administered within 4 hours of these agents.
  o Take SYNTHROID (levothyroxine sodium tablets, USP) as a single dose,
    preferably on an empty stomach, one-half to one hour before breakfast.
    Levothyroxine absorption is increased on an empty stomach.
  o Notify your physician if you experience any of the following symptoms:
    rapid or irregular heartbeat, chest pain, shortness of breath, leg cramps,
    headache, nervousness, irritability, sleeplessness, tremors, change in
    appetite, weight gain or loss, vomiting, diarrhea, excessive sweating,
    heat intolerance, fever, changes in menstrual periods, hives or skin rash,
    or any other unusual medical event.
  o Notify your physician or dentist that you are taking SYNTHROID prior to
    any surgery.
  o After a stable response has been established, it is important to have
    follow-up laboratory tests done, as ordered by your health care provider,
    at least annually.

This is the most important information to know about SYNTHROID. For more
information, talk with your health care provider.

Please click here for full Prescribing Information, or visit
www.rxabbvie.com/pdf/synthroid.pdf.

Synthroid is a prescription medication. For more information, visit
www.synthroid.com.

You are encouraged to report negative side effects of prescription drugs to
the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088 (1-800-332-1088).

If you cannot afford your medication, contact www.pparx.org or call the toll
free phone number (1-888-4PPA-NOW) (1-888-477-2669) for assistance.

About AbbVie
AbbVie (NYSE:ABBV) is a global, research-based biopharmaceutical company
formed in 2013 following separation from Abbott. AbbVie combines the focus and
passion of a leading-edge biotech with the expertise and structure of a
long-established pharmaceutical leader. The company's mission is to use its
expertise, dedicated people and unique approach to innovation to develop and
market advanced therapies that address some of the world's most complex and
serious diseases.

AbbVie aims to help patients live healthier lives and collaborate on
sustainable healthcare solutions. In 2013, AbbVie will employ approximately
21,000 people worldwide and market medicines in more than 170 countries. For
further information on the company and its people, portfolio and commitments,
please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our
Facebook or LinkedIn page.

[i] American Association of Clinical Endocrinologists (AACE). EmPower Website.
http://www.empoweryourhealth.org/thyroid-top-ten. Accessed January 9, 2013.
[ii] Georgetown University Medical Center. Basic Thyroid Information.
http://medicine.georgetown.edu/divisions/endocrinology/knowledge/204446.html.
Accessed January 9, 2013.
[iii] Mayo Clinic. Hypothyroidism Treatment.
http://www.mayoclinic.com/health/hypothyroidism/DS00353/DSECTION=treatments-and-drugs 
Accessed January 9, 2013.
[iv] Food and Drug Administration. Approved Drug Products with Therapeutic
Equivalence Evaluations (Orange Book); 30th ed. 2010. http://www.fda.org.
Accessed January 9, 2013.

SOURCE AbbVie

Contact: Roseanne Durril, (847) 938-6114, Tracy Sorrentino, (847) 937-8712
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement